istock-694728278_durktalsma
DurkTalsma / iStockphoto.com
1 June 2018AmericasJennifer Fox

Post-grant proceedings: shaping the biotech landscape

In March 2010, the Biologics Price Competition and Innovation Act (BPCIA) created an abbreviated pathway for licensing biosimilars and a 12-year exclusivity period for first licensed biologics. Shortly after, the America Invents Act (AIA) provided multiple changes to the patent system and established a variety of post-grant proceedings. Notably, the AIA established post-grant review (PGR) proceedings and inter partes review (IPR) proceedings.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
21 January 2026   The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.
Americas
19 January 2026   An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.
Americas
15 January 2026   The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.